Anticholinergic activity and cognitive decline in Parkinson's disease

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 81, Issue 2, 2010, Pages 129-

  Starkstein, Sergio E ^a  

^a FREMANTLE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT;

ANTICHOLINERGIC EFFECT; COGNITIVE DEFECT; DEPRESSION; DISEASE ASSOCIATION; DRUG EFFICACY; EDITORIAL; FOLLOW UP; MENTAL DETERIORATION; MENTAL DISEASE; MINI MENTAL STATE EXAMINATION; PARKINSON DISEASE; PRIORITY JOURNAL; SHORT TERM MEMORY;

CHOLINERGIC ANTAGONISTS; COGNITION DISORDERS; HUMANS; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; PREVALENCE; SEVERITY OF ILLNESS INDEX;

EID: 76549113819     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2009.194548     Document Type: Editorial

References (4)

1. Bedard MA, Pillon B, Dubois B, et al. Acute and long-term administration of anticholinergics in Parkinson's disease: specific effects on the subcortico-frontal syndrome. Brain Cogn 1999;40:289-313.
2. Cooper JA, Sagar HJ, Doherty SM, et al. Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease. A follow-up study of untreated patients. Brain 1992;115(Pt 6):1701-25.
3. Starkstein SE, Mayberg HS, Leiguarda R, et al. A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1992;55:377-82.
4. Menza M, Dobkin RD, Marin H, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 2009;72:886-92.